Fellowship, Medical Oncology, M.D. Anderson Cancer Center, Houston, TX & Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
Dr. Pedro Barata earned his medical degree from the New University of Lisbon in 2009 and completed his medical oncology fellowship in 2016. During his training, he spent one year in the USA rotating at the Phase I Department at M.D. Anderson Cancer Center, Houston, and at Taussig Cancer Center, Cleveland Clinic, Cleveland.
After completion of his fellowship, he was invited to join the genitourinary group at Taussig Cancer Center, where he had been working as the clinical experimental therapeutics fellow in clinical research with focus on genitourinary cancers.
Subsequently, Dr. Barata moved to Tulane University, where he continues his clinical and research work in the GU field and works to expand the program offered at Tulane Cancer Center. Dr. Barata leads the non-prostate medical oncology program offered at Tulane University.
As a result of his clinical and research work, Dr. Barata authored and co-authored more than 80 research publications in high-quality journals. Additionally, he has presented dozens of research abstracts at important national and international meetings and has authored textbook chapters and clinical reviews.
He has also served as a reviewer for prestigious peer-reviewed journals and currently serves as the Associate Editor for The Oncologist journal and Assistant Editor for Clinical Genitourinary Cancer journal. He is also a Member of the Editorial Board of the Translational Oncology journal.
Barata P, Agarwal N, Nussenzveig R, et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. Journal for ImmunoTherapy of Cancer 2020;8:e001065. doi: 10.1136/jitc-2020-001065.
Barata P, Layton, Lewis B, Sartor O, Next Generation of Androgen Deprivation Therapy Combined with Radiotherapy for N0M0 Prostate Cancer. Cancer J 2020; doi:10.1097/PPO.0000000000000428
Barata PC, Rini BI. Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin. 2017 Nov;67(6):507-524. doi: 10.3322/caac.21411. Epub 2017 Sep 29. PMID: 28961310.